OncXerna Therapeutics

OncXerna Therapeutics is a clinical stage precision medicine oncology company founded in 2018, with a mission to advance a new paradigm of precision oncology using a RNA-based approach. The company's innovative precision medicine platform, Xerna™, leverages artificial intelligence technologies and RNA expression-based biomarkers to match a specific patient’s tumor with the most suitable drugs for treatment. OncXerna's lead product candidate, navicixizumab, is currently undergoing studies in ovarian cancer, triple-negative breast cancer, and colorectal cancer, while another product candidate, bavituximab, is in Phase 2 clinical trials. The company's focus on developing novel therapies to treat solid tumors demonstrates its commitment to bringing meaningful new treatments to patients as soon as possible. Its $30.00M Venture Round investment at 03 March 2022, led by Company K Partners and K2 HealthVentures, is a testament to the confidence investors have in the potential of OncXerna's innovative approach to precision oncology. With its deep expertise in clinical development, OncXerna aims to accelerate the development, approval, and commercialization of its drug product candidates, ultimately contributing to the advancement of precision medicine in oncology.